enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. AbbVie taps Robert Michael to replace Gonzalez as CEO in July

    www.aol.com/news/abbvie-says-robert-michael...

    (Reuters) -AbbVie on Tuesday said Chief Operating Officer Robert Michael would succeed Richard Gonzalez to become the second-ever CEO of the drugmaker on July 1. Gonzalez, 70, who has been at the ...

  3. AbbVie - Wikipedia

    en.wikipedia.org/wiki/AbbVie

    On June 1, 2024, AbbVie's current President and Chief Operating Officer (COO) Robert Michael replaced Richard Gonzalez as CEO of AbbVie. Gonzalez will be the executive chairman. [38] In February 2024, AbbVie Inc. and Tentarix Biotherapeutics announced the beginning of a long-term collaboration in the discovery and development of opportunistic ...

  4. Abbvie Inc (ABBV) Chairman of the Board and CEO Richard A ...

    www.aol.com/news/abbvie-inc-abbv-chairman-board...

    Chairman of the Board and CEO of Abbvie Inc (30-Year Financial, Insider Trades) Richard A Gonzalez (insider trades) sold 231,604 shares of ABBV on 11/12/2020 at an average price of $96.88 a share.

  5. Is AbbVie the Best Dividend Stock for You? - AOL

    www.aol.com/abbvie-best-dividend-stock-114500950...

    AbbVie also replaced its leader as CEO Richard Gonzalez stepped down; Gonzalez had been at the helm since 2013. ... AbbVie's current lineup should allow it to perform well in the medium term ...

  6. Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO ... - AOL

    www.aol.com/news/worry-abbvie-inc-nyse-abbv...

    Rick Gonzalez has been the CEO of AbbVie Inc. (NYSE:ABBV) since 2012. First, this article will compare CEO... Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800 ...

  7. Pharmacyclics - Wikipedia

    en.wikipedia.org/wiki/Pharmacyclics

    In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. [6] The merger is expected to close in mid-2015. [7]

  8. Cerevel Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Cerevel_Therapeutics

    In May 2023, Coles resigned from his position as CEO, yet retained his role as board chairman of Cerevel. [7] In December 2023, American pharmaceutical company AbbVie announced its intention to acquire Cerevel for US$8.7 billion. [8] [9] [10] The acquisition was completed in August 2024 with Cerevel becoming a subsidiary of Abbvie. [11] [12]

  9. Know Your Management Team: Abbott Labs - AOL

    www.aol.com/news/2012-11-26-know-your-management...

    After the split, Miles White will remain chairman and CEO of Abbott while Rick Gonzalez, current VP of pharmaceutical products, will take over as AbbVie's chairman and CEO. White has held his post ...